🧬 GLP-1 R&D Pipeline Landscape Analysis¶
Report ID: MKI-GLP1PL-2026-001 | Release Date: July 2026
Coverage: Global GLP-1 R&D pipeline, multi-target agonists, oral formulations, clinical progress
1. R&D Pipeline Overview¶
As of mid-2026, the global GLP-1-related R&D pipeline exceeds 300 programs, of which approximately 60% are in the preclinical stage, 25% in Phase I-II clinical trials, 10% in Phase III/registration stage, and 5% have already submitted marketing applications.
Pipeline Trends
GLP-1 R&D is rapidly evolving from "injectable mono-target" toward "oral/long-acting + multi-target." 2025-2027 will be the critical validation period for the GLP-1 pipeline, with substantial Phase II and Phase III data expected to be released.
2. Drug Target Classification System¶
The GLP-1 pipeline can be categorized by target mechanism into the following main classes:
2.1 Mono-Target GLP-1 Receptor Agonists¶
| Classification | Representative Drug | Company | Clinical Stage |
|---|---|---|---|
| Injectable GLP-1 (long-acting) | Semaglutide 2.4mg (Wegovy upgrade) | Novo Nordisk | Phase III |
| Injectable GLP-1 (biweekly/monthly) | NNC0190-2021 (once monthly) | Novo Nordisk | Phase II |
| Oral GLP-1 | Oral semaglutide 50mg (weight loss dose) | Novo Nordisk | Phase III (filed 2025) |
| Oral GLP-1 | Oral tirzepatide | Eli Lilly | Phase III |
| Oral small molecule GLP-1 | Orforglipron | Eli Lilly | Phase III |
| Oral small molecule GLP-1 | GSBR-1290 | Structure Therapeutics | Phase II |
| Oral small molecule GLP-1 | EC5004 | Eccogene | Phase I |
2.2 GIP/GLP-1 Dual-Target Agonists¶
The dual-target mechanism achieves superior glycemic control and weight loss by simultaneously activating GIP and GLP-1 receptors:
| Drug | Company | Route | Clinical Stage | Weight Loss Data |
|---|---|---|---|---|
| Tirzepatide | Eli Lilly | Weekly injection | ✅ Approved | -22.5% @ 72 weeks |
| Oral tirzepatide | Eli Lilly | Daily oral | Phase III | Data pending |
| NNC0510-0411 | Novo Nordisk | Weekly injection | Phase II | Early data |
2.3 GLP-1/GCG Dual-Target Agonists¶
Activation of the glucagon receptor (GCG) increases energy expenditure while GLP-1 receptor activation suppresses appetite:
| Drug | Company | Route | Clinical Stage | Weight Loss Data |
|---|---|---|---|---|
| Mazdutide | Innovent Biologics | Weekly injection | NDA | -15.4% @ 48 weeks |
| Pemvidutide | Altimmune | Weekly injection | Phase II | -15.6% @ 48 weeks |
| Survodutide (BI 456906) | Boehringer Ingelheim/Zealand | Weekly injection | Phase III (MASH) | -14.9% @ 46 weeks |
| NN1700 | Novo Nordisk | Weekly injection | Phase II | Data pending |
2.4 GLP-1/GIP/GCG Triple-Target Agonists¶
Triple-target agonists are regarded as the "next-generation blockbusters" in the GLP-1 field:
| Drug | Company | Route | Clinical Stage | Weight Loss Data |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | Weekly injection | Phase III | -24.2% @ 48 weeks (Phase II) |
| LY3437943 (base version) | Eli Lilly | Weekly injection | Phase II | Data pending |
| NNC0364-0433 | Novo Nordisk | Weekly injection | Phase II | Data pending |
| HM15211 | Hanmi Pharmaceuticals | Weekly injection | Phase II | Data pending |
Retatrutide Worth Watching
Eli Lilly's Retatrutide achieved 24.2% weight reduction in Phase II clinical trials, approaching bariatric surgery results. If Phase III data is consistent, peak sales by 2030 could reach $30-40B.
3. Drug Delivery Innovation¶
3.1 Oral Formulation Pipeline¶
Oral GLP-1 is the key direction for addressing injection compliance issues:
| Technology Route | Representative Drug | Company | Stage | Bioavailability |
|---|---|---|---|---|
| SNAC absorption enhancement | Oral semaglutide | Novo Nordisk | Marketed | ~1% |
| Novel delivery technology | Oral tirzepatide | Eli Lilly | Phase III | Not disclosed |
| Small molecule GLP-1 | Orforglipron | Eli Lilly | Phase III | ~40-80% (oral) |
| Small molecule GLP-1 | GSBR-1290 | Structure Therapeutics | Phase II | Not disclosed |
| Permeation enhancement | NMB001 | Novo Nordisk/Partner | Phase I | Not disclosed |
3.2 Long-Acting Formulations¶
| Product | Dosing Frequency | Technology Route | Stage |
|---|---|---|---|
| NNC0190-2021 | Once monthly | Ultra-long-acting GLP-1 | Phase II |
| Exenatide microspheres (Bydureon BCise) | Once weekly | PLGA microspheres | Marketed |
| PEG-Loxenatide | Once weekly | PEGylation modification | Marketed (China) |
| LA-GLP-1 (various) | Biweekly to monthly | Multiple technology platforms | Multiple Phase I-II |
4. Global Clinical Trial Landscape¶
4.1 By Clinical Stage¶
| Stage | Pipeline Count | Share | Representative Programs |
|---|---|---|---|
| Marketed (2023-2026 approvals) | 6 | 2% | Tirzepatide, Oral semaglutide |
| NDA/Registration | 8 | 3% | Mazdutide, Oral tirzepatide |
| Phase III | 25+ | 8% | Retatrutide, Orforglipron, Survodutide |
| Phase II | 50+ | 17% | GSBR-1290, Pemvidutide |
| Phase I | 70+ | 23% | NNC0364-0433, EC5004 |
| Preclinical | 150+ | 47% | Undisclosed programs |
4.2 By Company Type¶
| Company Type | Pipeline Count | Success Rate (Est.) | Characteristics |
|---|---|---|---|
| Large pharma (Novo/Lilly) | 30+ | Highest | In-house tech + M&A, covering all targets |
| Mid-sized biotech (Altimmune, etc.) | 50+ | Medium | Focus on differentiated targets |
| Chinese pharma (Innovent/Hengrui, etc.) | 80+ | Medium | Focus on China market + global differentiation |
| Academic/Startup | 150+ | Low | Early-stage innovation exploration |
5. 2025-2027 Key Milestones¶
5.1 Expected Phase III/II Data Readouts for Key Programs¶
| Date | Program | Company | Indication | Type |
|---|---|---|---|---|
| 2025 H2 | Mazdutide | Innovent | T2D+Obesity | GCG/GLP-1 |
| 2025 H2 | Oral semaglutide 50mg | Novo Nordisk | Obesity | Oral GLP-1 |
| 2025 H2 | Survodutide | BI/Zealand | MASH | GCG/GLP-1 |
| 2026 H1 | Orforglipron | Eli Lilly | T2D+Obesity | Oral small molecule |
| 2026 H1 | Retatrutide | Eli Lilly | Obesity | Triple target |
| 2026 H2 | Oral tirzepatide | Eli Lilly | T2D+Obesity | Oral dual target |
| 2026-2027 | GSBR-1290 | Structure Therapeutics | T2D+Obesity | Oral small molecule |
| 2027 | Pemvidutide | Altimmune | Obesity+MASH | GCG/GLP-1 |
5.2 Key Indication Expansion Milestones¶
| Indication | Key Program | Data Readout | Expected Approval |
|---|---|---|---|
| MASH (NASH) | Survodutide | 2025 Phase III | 2027-2028 |
| MASH (NASH) | Retatrutide | 2026 Phase III | 2028 |
| CKD | Semaglutide (FLOW) | Positive | 2025 Approved |
| HFpEF | Semaglutide (STEP-HFpEF) | Positive | 2025 |
| Obstructive Sleep Apnea | Tirzepatide (SURMOUNT-OSA) | Positive | 2025 Approved |
| Alzheimer's Disease | Semaglutide (EVOKE) | 2026 Phase II | 2028+ (if positive) |
| Peripheral Artery Disease | Semaglutide | 2027 Phase II | 2029+ |
6. China GLP-1 Pipeline Panorama¶
6.1 China GLP-1 Pipeline Count¶
| Company Type | Pipeline Count | Representative Companies |
|---|---|---|
| Domestic innovative pharma | 25+ | Innovent, Hengrui, Gan & Lee |
| Generic pharma | 40+ | Jiuyuan Gene, Livzon, CSPC, Qilu Pharma |
| CDMO proprietary programs | 10+ | Sinopeptide, Shengnuo Biotechnology |
| Total | 75+ | — |
6.2 Global Differentiation of China's Innovative GLP-1 Pipeline¶
| Differentiation Direction | Representative Company | Program |
|---|---|---|
| GCG/GLP-1 dual target (global first NDA) | Innovent Biologics | Mazdutide |
| Weekly oral GLP-1 | Hengrui Medicine | Oral GLP-1 (Phase I) |
| GLP-1 long-acting fusion protein | Gan & Lee Pharma | GZR18 |
| GLP-1 + other target bispecific | Hansoh Pharma | Undisclosed |
7. R&D Trend Summary¶
7.1 Key Trends for the Next 5 Years¶
- Oralization: By 2030, oral GLP-1 expected to account for 20-25% of the market; small molecule GLP-1 will be the largest incremental driver
- Multi-Target: Triple-target agonists (exemplified by Retatrutide) expected to become the new standard post-2030
- Indication Expansion: Extension from metabolic diseases to CNS, cardiovascular, inflammatory indications will give the GLP-1 pipeline "long-tail value"
- Long-Acting: Biweekly/monthly GLP-1 formulations will further improve compliance
- AI-Assisted Discovery: AI-driven GLP-1 analog design and oral small molecule screening accelerating pipeline advancement
7.2 Risk Factors¶
| Risk | Impact Level | Description |
|---|---|---|
| Safety signals | ★★★★☆ | Long-term safety of thyroid C-cell tumors, pancreatitis, etc. requires ongoing monitoring |
| Phase III data misses expectations | ★★★☆☆ | Retatrutide early data impressive but Phase III may underperform |
| Regulatory tightening | ★★★☆☆ | Regulatory scrutiny on obesity drug safety and compliance increasing |
| Intensifying market competition | ★★★★☆ | Crowded pipeline making differentiation more difficult for me-too products |
Conclusion¶
The GLP-1 R&D pipeline is in a "golden age." Multi-target agonists (especially triple-target), oral small molecule GLP-1s, and indication expansion into large markets such as MASH/AD/CKD give this field at least 10+ years of high growth potential. For Chinese companies, the global launch of differentiated programs such as Mazdutide will be a milestone validating China's peptide innovative drug R&D capabilities.
Pipeline Data Sources
This report's pipeline data is compiled from ClinicalTrials.gov, company announcements, and R&D day materials. Some early-stage pipeline data may be incomplete.
Learn more about peptide R&D pipelines → Visit SENO Biotechnology Platforms. SENO Biotechnology continuously tracks global peptide R&D developments, providing CDMO services to accelerate your peptide innovative drug from discovery to commercialization.